Peregrine Capital Management LLC Sells 15,789 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Peregrine Capital Management LLC lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 12.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 114,199 shares of the medical equipment provider's stock after selling 15,789 shares during the quarter. Intuitive Surgical comprises 1.9% of Peregrine Capital Management LLC's portfolio, making the stock its 11th largest position. Peregrine Capital Management LLC's holdings in Intuitive Surgical were worth $56,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ISRG. AlphaCore Capital LLC grew its holdings in shares of Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after acquiring an additional 18 shares during the period. Accredited Investors Inc. grew its stake in Intuitive Surgical by 1.9% in the fourth quarter. Accredited Investors Inc. now owns 1,040 shares of the medical equipment provider's stock worth $543,000 after purchasing an additional 19 shares during the period. Second Line Capital LLC raised its holdings in Intuitive Surgical by 3.4% in the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after purchasing an additional 19 shares in the last quarter. Colonial Trust Co SC lifted its position in Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock valued at $128,000 after buying an additional 20 shares during the period. Finally, Crown Wealth Group LLC lifted its position in Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock valued at $218,000 after buying an additional 20 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president owned 5,224 shares in the company, valued at $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,998 shares of company stock worth $2,611,577. Company insiders own 0.70% of the company's stock.

Intuitive Surgical Stock Down 1.7%

Shares of Intuitive Surgical stock traded down $9.36 during trading hours on Tuesday, reaching $534.05. 422,425 shares of the stock traded hands, compared to its average volume of 1,664,566. The firm has a market capitalization of $191.41 billion, a price-to-earnings ratio of 78.42, a P/E/G ratio of 5.66 and a beta of 1.67. The company has a 50 day moving average price of $533.58 and a 200 day moving average price of $536.72. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The business had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same period last year, the firm earned $1.50 earnings per share. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

ISRG has been the subject of several research reports. Truist Financial decreased their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Royal Bank Of Canada cut their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Citigroup reaffirmed a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Evercore ISI dropped their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research report on Wednesday, April 23rd. Finally, Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $588.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.